ENTA
Enanta Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +6.7% ·
share flow -12.3% ·
net new positions +6.2%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 56 | -3 | 10.74M | $156.55M | +2 | −5 |
| Q1 2026 | 62 | -2 | 14.86M | $187.69M | +5 | −7 |
| Q4 2025 | 64 | +3 | 16.10M | $253.79M | +3 | — |
| Q3 2025 | 16 | +1 | 7.96M | $95.31M | +2 | −1 |
| Q2 2025 | 12 | 0 | 8.38M | $63.38M | — | — |
| Q1 2025 | 9 | -2 | 4.49M | $24.81M | — | −2 |
| Q4 2024 | 11 | -1 | 4.05M | $23.26M | — | −1 |
| Q3 2024 | 11 | +2 | 4.15M | $43.00M | +2 | — |
| Q2 2024 | 9 | — | 3.87M | $50.19M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 1.94M | -1.9% | $23.21M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 2 | BlackRock ✦ (passive) | 1.83M | -0.8% | $21.94M | 0.0% | ▼ Trim | 2 | SEC ↗ ×9 |
| 3 | Millennium Management ✦ | 948.08K | -35.0% | $11.35M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 493.19K | +1.5% | $5.90M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 5 | Renaissance Technologies ✦ | 479.60K | +2.1% | $5.74M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 6 | State Street Global Advisors ✦ (passive) | 471.99K | +0.4% | $5.65M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Point72 Asset Management ✦ | 300.00K | New | $3.59M | 0.0% | New | 1 | SEC ↗ |
| 8 | Morgan Stanley ✦ | 282.63K | — | $3.38M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 9 | Marshall Wace ✦ | 275.39K | -67.9% | $3.30M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 10 | JPMorgan Chase ✦ | 247.63K | — | $2.96M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 11 | AQR Capital Management ✦ | 226.84K | -42.7% | $2.72M | 0.0% | ▼ Trim | 6 | SEC ↗ ×5 |
| 12 | D. E. Shaw & Co. ✦ | 225.74K | -20.0% | $2.70M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 13 | Goldman Sachs Group ✦ | 166.43K | — | $1.99M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 14 | Two Sigma Investments ✦ | 60.72K | -22.6% | $726,842 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 10.15K | New | $122,000 | 0.0% | New | 1 | SEC ↗ |
| 16 | Fidelity (FMR) ✦ | 1.78K | -0.3% | $21,363 | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $3.59M | 0.0% |
| T. Rowe Price | $122,000 | 0.0% |
Exited
| Citadel Advisors | $447,129 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 131 holders, 26.72M shares, $290.62M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.